Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Chapman · SciRah

Researcher profile · Semantic Scholar

R. Chapman

Share profile

R. Chapman — researcher profile on SciRah

h-index: 31
Works: 89
Citations: 3,899

Most-cited papers

Predictors of adherence with antihypertensive and lipid-lowering therapy.
R. Chapman, J. Benner, A. Petrilla, J. Tierce +3 more
2005Archives of Internal Medicine576 citations
Semantic Scholar
The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys
H. Bays, R. Chapman, S. Grandy
2007International journal of clinical practice568 citations Open access
Semantic Scholar
United States Valuation of EQ-5D-5L Health States Using an International Protocol.
A. Pickard, E. Law, R. Jiang, E. Pullenayegum +8 more
2019Value in Health337 citations Open access
Semantic Scholar
Systematic overview of cost-utility assessments in oncology.
C. Earle, R. Chapman, C. Baker, C. Bell +3 more
2000Journal of Clinical Oncology306 citations
Semantic Scholar
A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies
R. Chapman, P. W. Stone, Eileen A. Sandberg, C. Bell +1 more
2000Medical decision making168 citations
Semantic Scholar
Predictors of Adherence to Concomitant Antihypertensive and Lipid-Lowering Medications in Older Adults
R. Chapman, A. Petrilla, J. Benner, J. S. Schwartz +1 more
2008Drugs & Aging121 citations
Semantic Scholar
Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy.
J. Benner, R. Chapman, A. Petrilla, Simon S. K. Tang +2 more
2009American Journal of Health-System Pharmacy115 citations
Semantic Scholar
When does quality-adjusting life-years matter in cost-effectiveness analysis?
R. Chapman, M. Berger, M. Weinstein, J. Weeks +2 more
2004Health Economics114 citations
Semantic Scholar
An Off-the-Shelf Help List
C. Bell, R. Chapman, P. Stone, Eileen A. Sandberg +1 more
2001Medical decision making102 citations
Semantic Scholar
Cost-utility analyses of clinical preventive services1
P. Stone, S. Teutsch, R. Chapman, C. Bell +2 more
200096 citations Open access
Semantic Scholar
Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma
M. Whittington, R. McQueen, D. A. Ollendorf, Varun M. Kumar +4 more
2019JAMA Network Open84 citations Open access
Semantic Scholar
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia
M. Whittington, R. McQueen, D. Ollendorf, Varun M. Kumar +4 more
2018JAMA pediatrics79 citations Open access
Semantic Scholar
Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
M. Whittington, R. McQueen, D. A. Ollendorf, Jeffrey A. Tice +3 more
2017Annals of Allergy, Asthma & Immunology78 citations
Semantic Scholar
Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)
H. Bays, D. D. Bazata, N. Clark, James R. Iii Gavin +7 more
2007BMC Public Health73 citations Open access
Semantic Scholar
Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.
D. Ollendorf, R. Chapman, S. Pearson
2018Value in Health69 citations Open access
Semantic Scholar
Cost-Effectiveness of SacubitrilValsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction
Alexander T. Sandhu, D. A. Ollendorf, R. Chapman, S. Pearson +1 more
2017Annals of Internal Medicine64 citations
Semantic Scholar
Cost-Effectiveness of SacubitrilValsartan in Patients With Heart Failure With Reduced Ejection Fraction
Alexander T. Sandhu, D. Ollendorf, R. Chapman, S. Pearson +1 more
2016Annals of Internal Medicine59 citations
Semantic Scholar
Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease.
M. Zimmermann, Solomon J. Lubinga, R. Banken, D. Rind +5 more
2019Value in Health56 citations
Semantic Scholar
Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting
R. Straka, Larry Z. Liu, P. Girase, A. Delorenzo +1 more
2009Cardiovascular Diabetology55 citations Open access
Semantic Scholar
The cost and effectiveness of adherence‐improving interventions for antihypertensive and lipid‐lowering drugs *
R. Chapman, C. P. Ferrufino, S. Kowal, P. Classi +1 more
2009International journal of clinical practice53 citations Open access
Semantic Scholar
Red cell transfusions in total knee and total hip replacement surgery
D. Surgenor, E. Wallace, W. Churchill, S.-H.-S. Hao +2 more
199147 citations
Semantic Scholar
Open Access Research Article Association between Adherence to Calcium-channel Blocker and Statin Medications and Likelihood of Cardiovascular Events among Us Managed Care Enrollees
R. Chapman, J. Yeaw, C. Roberts
47 citations
Semantic Scholar
The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.
R. Chapman, S. Kowal, S. Cherry, C. P. Ferrufino +2 more
2010Value in Health45 citations Open access
Semantic Scholar
Can We Better Prioritize Resources for Cost-Utility Research?
P. Neumann, A. Rosen, D. Greenberg, N. Olchanski +7 more
2005Medical decision making44 citations
Semantic Scholar
Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
M. Zimmermann, E. Brouwer, J. Tice, M. Seidner +5 more
2018CNS Drugs43 citations
Semantic Scholar
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States
J. Carlson, G. Guzauskas, R. Chapman, Patricia G. Synnott +5 more
2018Journal of Managed Care & Specialty Pharmacy40 citations Open access
Semantic Scholar
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
M. Hussein, R. Chapman, J. Benner, Simon S. K. Tang +3 more
2010American Journal of Cardiovascular Drugs39 citations
Semantic Scholar
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
N. Hendrix, D. Ollendorf, R. Chapman, Anne M. Loos +5 more
2018Journal of Managed Care & Specialty Pharmacy37 citations Open access
Semantic Scholar
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
P. Thokala, M. Stevenson, Varun M. Kumar, Shi-Jie Ren +2 more
2020Cost Effectiveness and Resource Allocation36 citations Open access
Semantic Scholar
Determining initial and follow-up costs of cardiovascular events in a US managed care population
R. Chapman, Larry Z. Liu, P. Girase, R. Straka
2011BMC Cardiovascular Disorders35 citations Open access
Semantic Scholar
PCV5 PREDICTORS OF ADHERENCE WITH CONCOMITANT ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY
R. Chapman, J. Benner, A. Petrilla, J. Tierce +2 more
200433 citations Open access
Semantic Scholar
New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?
S. Pearson, D. Ollendorf, R. Chapman
2019Value in Health30 citations Open access
Semantic Scholar
Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
G. Guzauskas, D. Rind, K. Fazioli, R. Chapman +2 more
2021Journal of Managed Care & Specialty Pharmacy23 citations Open access
Semantic Scholar
Generic and therapeutic statin switches and disruptions in therapy
R. Chapman, J. Benner, P. Girase, M. Benigno +3 more
2009Current Medical Research and Opinion23 citations
Semantic Scholar
Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis
E. Pelletier, M. Pawaskar, Paula J. Smith, J. Best +1 more
2012Journal of Medical Economics20 citations
Semantic Scholar
The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States
O. Mandrik, J. Fotheringham, Shi-Jie Ren, J. Tice +6 more
2022American Society of Nephrology. Clinical Journal18 citations Open access
Semantic Scholar
Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia.
H. Bays, R. Chapman, K. Fox, S. Grandy
2008Current Medical Research and Opinion15 citations
Semantic Scholar
Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?
R. Chapman, E. Pelletier, Paula J. Smith, C. Roberts
2009Patient Preference and Adherence12 citations Open access
Semantic Scholar
Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Varun M. Kumar, F. Agboola, Patricia G. Synnott, C. Segel +4 more
2019Value in Health11 citations Open access
Semantic Scholar
Does a Single-Pill Antihypertensive/Lipid-Lowering Regimen Improve Adherence in US Managed Care Enrollees?
M. Hussein, R. Chapman, J. Benner, Simon S. K. Tang +3 more
201011 citations
Semantic Scholar
Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States
J. Carlson, S. Walton, A. Basu, R. Chapman +7 more
2019PharmacoEconomics (Auckland)10 citations Open access
Semantic Scholar
The association between insurance coverage for insulin pen needles and healthcare resource utilization among insulin-dependent patients with diabetes in China
L. Ji, A. Chandran, T. Inocencio, Zi-Lin Sun +5 more
2018BMC Health Services Research10 citations Open access
Semantic Scholar
Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia*
H. Bays, R. Chapman, K. Fox, S. Grandy
200810 citations
Semantic Scholar
Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer.
Mrinmayee Joshi, S. Atlas, M. Beinfeld, R. Chapman +3 more
2022Value in Health9 citations
Semantic Scholar
Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
M. Whittington, R. McQueen, D. A. Ollendorf, R. Chapman +4 more
2019Journal of Managed Care & Specialty Pharmacy8 citations Open access
Semantic Scholar
Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets.
R. Chapman, Varun M. Kumar, M. Whittington, S. Pearson
2021Value in Health7 citations Open access
Semantic Scholar
Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation.
Kael Wherry, I. Williamson, R. Chapman, K. Kuntz
2020Value in Health7 citations Open access
Semantic Scholar
Drug titration patterns and HbA1c levels in type 2 diabetes
J. R. Maclean, R. Chapman, C. P. Ferrufino, G. Krishnarajah
2009International journal of clinical practice7 citations Open access
Semantic Scholar
Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies
J. Gaultney, Jacoline C. Bouvy, R. Chapman, A. Upton +5 more
2021Applied Health Economics and Health Policy6 citations
Semantic Scholar
Preferences for Treatments for Major Depressive Disorder: Formative Qualitative Research Using the Patient Experience
S. dosReis, L. Bozzi, Beverly Butler, Richard Z. Xie +4 more
2022Patient5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Pearson×12
Invite
S. Pearson — researcher profile on SciRah
Varun M. Kumar×8
Invite
Varun M. Kumar — researcher profile on SciRah
D. Ollendorf×8
Invite
D. Ollendorf — researcher profile on SciRah
J. Benner×7
Invite
J. Benner — researcher profile on SciRah

×6

Invite

M. Whittington — researcher profile on SciRah

Invite

R. McQueen — researcher profile on SciRah

Jonathan D. Campbell×5

Invite

Jonathan D. Campbell — researcher profile on SciRah

Invite

A. Petrilla — researcher profile on SciRah

Invite

H. Bays — researcher profile on SciRah

Invite

S. Grandy — researcher profile on SciRah

Invite

P. Stone — researcher profile on SciRah

Peter J. Neumann×4

Invite

Peter J. Neumann — researcher profile on SciRah